Identification of an activation‑related protein in B cells in the ABO incompatible condition

Cao,Jingsong; Chen,Cong; Liu,Luogen; Zhang,Yunsheng; Zhou,Hong; Xiao,Jianhua; Wang,Yi

doi:10.3892/etm.2019.8234

Identification of an activation‑related protein in B cells in the ABO incompatible condition

Authors:
- Jingsong Cao
- Cong Chen
- Luogen Liu
- Yunsheng Zhang
- Hong Zhou
- Jianhua Xiao
- Yi Wang
View Affiliations

Affiliations: Clinical Research Center, Institute of Pathogenic Biology, Medical College, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, University of South China, Hengyang, Hunan 421001, P.R. China, The Second Hospital, University of South China, Hengyang, Hunan 421001, P.R. China, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: November 22, 2019 https://doi.org/10.3892/etm.2019.8234
Pages: 741-747

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In ABO‑incompatible (ABOi) kidney transplantation (KT), antibodies can mediate immunological accommodation or immune rejection, but the mechanism by which B cells are induced to produce antibodies with different functions is still unclear. Previous research established an ABOi kidney cell model and identified that haptoglobin (HP) is associated with the activation of lymphocytes. In the present study, the results of a flow cytometric assay demonstrated that HP was expressed by B cells. Moreover, dot‑ELISA and ELISA analyses showed that the concentrations of total IgG, blood group B antibody, IgG1, IgG2 and IgG4 were all significantly increased in the cell model. In addition, dot‑ELISA and haptoglobin level analyses showed that HP protein expression was significantly increased, while RT‑qPCR assay indicated that HP was significantly reduced at the mRNA level. Furthermore, bioinformatics analysis showed that HP could interact with Smad3, and the HP‑Smad3 complex was detected in a peripheral blood mononuclear cell (PBMC) protein extract by a dot‑ELISA method. This research revealed that HP was involved in the process of B‑cell activation by interacting with Smad3, and the results will be helpful to reveal the mechanism of B‑cell activation in ABOi‑KT.

View Figures

View References

1	Koo TY and Yang J: Current progress in ABO-incompatible kidney transplantation. Kidney Res Clin Pract. 34:170–179. 2015. View Article : Google Scholar : PubMed/NCBI
2	Takahashi K and Saito K: ABO-incompatible kidney transplantation. Transplant Rev (Orlando). 27:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
3	Takahashi K, Tanabe K, Ooba S, Yagisawa T, Nakazawa H, Teraoka S, Hayasaka Y, Kawaguchi H, Ito K, Toma H, et al: Prophylactic use of a new immunosuppressive agent, deoxyspergualin, in patients with kidney transplantation from ABO-incompatible or preformed antibody-positive donors. Transplant Proc. 23:1078–1082. 1991.PubMed/NCBI
4	Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM and Puliatti C: ABO incompatible renal transplants: Good or bad? World J Transplant. 4:18–29. 2014. View Article : Google Scholar : PubMed/NCBI
5	Morimoto H, Ide K, Tanaka Y, Ishiyama K, Ohira M, Tahara H, Akita T, Tanaka J and Ohdan H: Different sensitivity of rituximab-treatment to B-cells between ABO-incompatible kidney and liver transplantation. Hum Immunol. 77:456–463. 2016. View Article : Google Scholar : PubMed/NCBI
6	Lee KW, Park JB, Oh DK, Na BG, Choi JY, Cho WT, Lee SH, Park HJ, Cho D, Huh WS and Kim SJ: Short-term outcomes of ABO-incompatible living donor kidney transplantation with uniform protocol: Significance of baseline anti-ABO titer. Transplant Proc. 48:820–826. 2016. View Article : Google Scholar : PubMed/NCBI
7	Makroo RN, Nayak S, Chowdhry M, Jasuja S, Sagar G, Rosamma NL and Thakur UK: Role of therapeutic plasma exchange in reducing ABO titers in patients undergoing ABO-incompatible renal transplant. Apollo Medicine. 13:31–36. 2016. View Article : Google Scholar
8	Snell GI, Davis AK, Menahem S, Kotecha S, Whitford HM, Levvey BJ, Paraskeva M, Webb A, Westall GW and Walker RG: ABO incompatible renal transplantation following lung transplantation. Transpl Immunol. 39:30–33. 2016. View Article : Google Scholar : PubMed/NCBI
9	Tanabe T, Ishida H, Horita S, Yamaguchi Y, Toma H and Tanabe K: Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation. Transpl Immunol. 25:1–6. 2011. View Article : Google Scholar : PubMed/NCBI
10	Kim J, Kim S, Hwang IS, Choi JR, Lee JG, Kim YS, Kim MS and Kim HO: Effects of neutralization by soluble ABH antigens produced by transplanted kidneys from ABO-incompatible secretor donors. Ann Lab Med. 37:254–260. 2017. View Article : Google Scholar : PubMed/NCBI
11	Chen C and Guo H: Transplantation pathology. People's Medical Publishing House (edition 1); Beijing, China: 2009
12	Cao J, Chen C, Gao Y, Hu L, Liang Y and Xiao J: Identification of a protein associated with the activity of cytokine-induced killer cells. Oncol Lett. 14:6937–6942. 2017.PubMed/NCBI
13	Cao J, Liu L, Zhang Y, Xiao J and Wang Y: The influence of HK2 blood group antigen on human B cell activation for ABOi-KT conditions. BMC Immunol. 18:492017. View Article : Google Scholar : PubMed/NCBI
14	Huang J, Kan Q, La n, Zhao X, Zhang Z, Yang S, Li H, Wang L, Xu L, Cheng Z and Zhang Y: Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer. Int Immunopharmacol. 46:170–177. 2017. View Article : Google Scholar : PubMed/NCBI
15	Khalili I, Koch M, Thaiss F, Plaetke R, Bruegger J and Peine S: Systematic comparison of IgM and IgG ABO antibody titers by using tube and gel card techniques and its relevance for ABO-incompatible kidney transplantation. Clin Lab. 63:1393–1401. 2017. View Article : Google Scholar : PubMed/NCBI
16	Tan W, Wang F, Guo D, Ke Y, Shen Y, Lv C and Zhang M: High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients. Int J Rheum Dis. 19:482–489. 2016. View Article : Google Scholar : PubMed/NCBI
17	Delanghe JR, Langlois MR and De Buyzere ML: Haptoglobin polymorphism: A key factor in the proatherogenic role of B cells? Atherosclerosis. 217:80–82. 2011. View Article : Google Scholar : PubMed/NCBI
18	Huntoon KM, Russell L, Tracy E, Barbour KW, Li Q, Shrikant PA, Berger FG, Garrett-Sinha LA and Baumann H: A unique form of haptoglobin produced by murine hematopoietic cells supports B-cell survival, differentiation and immune response. Mol Immunol. 55:345–354. 2013. View Article : Google Scholar : PubMed/NCBI
19	Huang J, Doria-Rose NA, Longo NS, Laub L, Lin CL, Turk E, Kang BH, Migueles SA, Bailer RT, Mascola JR and Connors M: Isolation of human monoclonal antibodies from peripheral blood B cells. Nat Protoc. 8:1907–1915. 2013. View Article : Google Scholar : PubMed/NCBI
20	Liu Y, Beyer A and Aebersold R: On the dependency of cellular protein levels on mRNA abundance. Cell. 165:535–550. 2016. View Article : Google Scholar : PubMed/NCBI
21	Hao Y, Yang X, Zhang D, Luo J and Chen R: Long noncoding RNA LINC01186, regulated by TGF-β/SMAD3, inhibits migration and invasion through Epithelial-Mesenchymal-Transition in lung cancer. Gene. 608:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
22	Letterio JJ: Murine models define the role of TGF-beta as a master regulator of immune cell function. Cytokine Growth Factor Rev. 11:81–87. 2000. View Article : Google Scholar : PubMed/NCBI
23	DiRenzo DM, Chaudhary MA, Shi X, Franco SR, Zent J, Wang K, Guo LW and Kent KC: A crosstalk between TGF-β/Smad3 and Wnt/β-catenin pathways promotes vascular smooth muscle cell proliferation. Cell Signal. 28:498–505. 2016. View Article : Google Scholar : PubMed/NCBI
24	Kashiwagi I, Morita R, Schichita T, Komai K, Saeki K, Matsumoto M, Takeda K, Nomura M, Hayashi A, Kanai T and Yoshimura A: Smad2 and Smad3 inversely regulate TGF-β autoinduction in Clostridium butyricum-activated dendritic cells. Immunity. 43:65–79. 2015. View Article : Google Scholar : PubMed/NCBI
25	Lan HY: Smads as therapeutic targets for chronic kidney disease. Kidney Res Clin Pract. 31:4–11. 2012. View Article : Google Scholar : PubMed/NCBI
26	McKarns SC, Letterio JJ and Kaminski NE: Concentration-dependent bifunctional effect of TGF-beta 1 on immunoglobulin production: A role for Smad3 in IgA production in vitro. Int Immunopharmacol. 3:1761–1774. 2003. View Article : Google Scholar : PubMed/NCBI
27	Zhang Y and Derynck R: Transcriptional regulation of the transforming growth factor-beta-inducible mouse germ line Ig alpha constant region gene by functional cooperation of Smad, CREB, and AML family members. J Biol Chem. 275:16979–16985. 2000. View Article : Google Scholar : PubMed/NCBI
28	Chacko BM, Qin BY, Tiwari A, Shi G, Lam S, Hayward LJ, De Caestecker M and Lin K: Structural basis of heteromeric smad protein assembly in TGF-beta signaling. Mol Cell. 15:813–823. 2004. View Article : Google Scholar : PubMed/NCBI